The primary endpoint of the CheckMate 025 trial was overall survival. Nivolumab was found to significantly extend the median OS to 25 months compared to 19.6 months with everolimus. Additionally, the objective response rate (ORR) was higher in the nivolumab group (25%) compared to the everolimus group (5%). These results underscore the potential of nivolumab to enhance survival outcomes in RCC patients.
